Kornimate/medical-research-clean huggingface dataset:
38 week extension study to cain457c2303

Conditions: Uveitis

Summary: a 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in behçet's patients with posterior or panuveitis treated with ain457 vs placebo adjunctive to standard-of-care immunosuppressive therapy


Eligibility criteria:
inclusion criteria: - exclusion criteria: -

Keywords: uveitis
dextrose therapy on physical therapy in subdeltoid bursitis

Conditions: Subdeltoid Bursitis; Injection; Effect of Drug

Summary: physical therapy and hypertonic dextrose prolotherapy are often used to treat subdeltoid bursitis. this study aims to investigate the effects of hypertonic dextrose injection on physical therapy through a double-blind, randomized study.

a double-blind, randomized, placebo-controlled clinical trial will be conducted to collect 44 patients with subdeltoid bursitis. in the first week and the third week, a total of 20% hypertonic dextrose 10 ml (experimental group) and normal saline 10 ml (placebo group) will be injected under sonographic guidance, and physical therapy (hot shoulder pack, interference wave, and exercise for 20 minutes each) 3 times per week for one month will be arranged. shoulder pain by visual analog scale, function (including disabilities of the arm, shoulder, and hand: dash and shoulder pain and disability index: spadi), quality of life (brief version of the world health organization quality of life scale: whoqol-bref) and high-resolution ultrasound examination will be arranged at before treatment, one week after treatment (i.e., one week after injection), one month, and three months after injection.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of subdeltoid bursitis age 20 or older 20 at least one positive in the painful arc, neer test, or hawkins test can attend 3 months of intervention and follow up exclusion criteria: * history of malignancy previous shoulder operation or injury previous shoulder injections in the past 3 months

Keywords: subdeltoid bursitis dextrose physical therapy
how neurofibromatosis type 1 (nf1) affects schoolwork and self-esteem

Conditions: Neurofibromatosis Type 1

Summary: the study will seek to determine whether there is a corresponding deficit in school performance for teenagers with nf1. secondly, the study seeks to explore the issue of self-esteem in teenagers with nf1.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of neurofibromatosis type 1 exclusion criteria: * neurofibromatosis type 2 * schwannomatosis

Keywords: neurofibromatosis
the impact of passive heat treatment on glycaemic response during an oral glucose tolerance test in diabetic patients

Conditions: Diabetes Mellitus, Type 2

Summary: type 2 diabetes mellitus (t2dm) is a metabolic disease with a rapidly increasing incidence world-wide. the disease is characterizedby a decreased glucose tolerance as a result of insulin resistance, resulting in poor blood glycaemic control. blood glucose loweringmedications are widely available, but their effect stagnates as t2dm progresses. new treatment regimens are required to combatthe disease. although therapies such as physical exercise have been shown to induce beneficial effects on glycaemic control int2dm patients, not all patients are able to perform exercise. passive heating treatment (pht) might be an alternative strategy toreduce insulin resistance, as it has been postulated to have comparable effects on the cardiovascular system as exercise. pht hasbeen linked to numerous health benefits, including improved cardiovascular- and pulmonary function, pain alleviation and metabolichealth. in addition, long term use of pht shows promising effects on glycaemic control in t2dm patients. however, the acute effectsof pht on glucoregulation are yet to be determined. therefore, in this study we will assess the acute impact of passive heat treatment on the post-prandial glycaemic response during an ogtt in t2dm patients


Eligibility criteria:
inclusion criteria: * aged ≥50 years old * body mass index 18.5 - 35 kg/m2 * dm type 2 * using oral blood glucose lowering medication * able to give informed consent exclusion criteria: * insulin dependence * changes in diabetes medication in the past 3 months * allergy for one of the food items used * \>5% weight change in the previous 6 months * participating in a structured (progressive) exercise program, or in the past 3 months. * frequent (once per week or more) user of infrared (or traditional) sauna in the past 3 months * inability to tolerate sauna/high temperatures * smoking * diagnosed with cardiovascular disease (e.g. unstable angina pectoris or recent myocardial infarction), kidney failure (egfr \< 60 ml/min/1.73m2), rheumatoid arthritis * diagnosed musculoskeletal, gi tract, metabolic (except diabetes) or pulmonary (e.g. copd) disorders that are expected to influence study outcomes * having a pacemaker, defibrillator, or any other type of metal implant
grid therapy for tumors of the head, neck, thorax, abdomen, pelvis and extremities.

Conditions: Radiation Therapy Complication; Tumor Neck; Tumor Abdomen

Summary: this study is an observational registry study evaluating the clinical outcomes of grid therapy. subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this study. once consent has been obtained, baseline adverse event and qol data will be collected and subjects will undergo grid therapy and follow-up at 2-4 weeks (for toxicity), and 3-6 months (for toxicities and radiographic control) then per clinical discretion up to 1 year. patients will be evaluated according to the physician's standard practice and discretion. patient data will be drawn from the patients' medical records and reported by means of a web-based electronic data collection (edc) system. patients will be considered "on study" until 60 months of observation has occurred, withdrawal of consent, lost to follow-up, or study closure. see below for the clinical visit flowchart for data collected at baseline and standard clinic visits.


Eligibility criteria:
inclusion criteria: * patients with tumors of the head and neck, thorax, abdomen, pelvis, and extremities. * age ≥ 18 years. * histological confirmation of oncologic diagnosis. * completed oncologic imaging (per discretion of treating physician) * ecog performance status 0-3 * ability to complete questionnaire(s) by themselves or with assistance. * willing to return to enrolling institution for follow-up (during the active monitoring phase of the study). * provide informed written consent. exclusion criteria: * any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects: * pregnant women * nursing women * women of childbearing potential who are unwilling to employ adequate contraception * co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. * immunocompromised patients and patients known to be hiv positive and currently receiving antiretroviral therapy. note: patients known to be hiv positive, but without clinical evidence of an immunocompromised state, are eligible for this trial. * uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
mesotherapy versus systemic therapyin treatment of migraine headache

Conditions: Migraine Headache

Summary: introduction:migraine is a prevalent disabling primary headache disorder which is classified in two major types; migraine without aura and migraine with aura. the aim of this study was to compare the efficiency of mesotherapy with systemic therapy in pain controlin patients with headache related tomigraine without aura. methods: we conducted this prospective parallel randomized controlled trial with the patients admitted to the emergency department with headache related to migraine without aura. one group was treated with mesotherapy, and the control group with intravenous dexketoprofen. changes in pain intensity at 30th minute, 60th minute, 120th minute and 24th hours after treatment using visual analogue scale (vas), need to use analgesic drug within 24 hours,re-admission with same complaint to emergency department (ed) within 72 hours, and adverse effect rate of the methods were compared between groups.


Eligibility criteria:
inclusion criteria: * 18 years and older age, and (2) * admission to emergency department (ed) with headache related to the migraine without aura. exclusion criteria: * taking analgesic drugs before admission, * having vas score of lower than 4 on admission, * having diabetes mellitus, * body mass index\>30 kg/m2, * pregnancy, * lactation, * having active bleeding or bleeding disorder, * having active or recurrent gastrointestinal hemorrhage or ulcer, or history of these conditions, * having a serious or life-threatening condition (stroke, intracranial hemorrhage, heart attack, cardiac tamponade, pneumothorax, hemothorax, flail chest, etc.).

Keywords: mesotherapy migraine
the effect of web-based and face-to-face training given to office workers on health beliefs and physical activity levels regarding obesity

Conditions: Obesity

Summary: aim: this study was evaluated to compare the effects of web-based and face-to- face education given to office workers on health beliefs and physical activity levels towards obesity. material and method: the research was conducted as a randomized controlled experimental study. the study population consisted of 768 office workers between february 2020 and april 2021, and the sample of the research consisted of 90 individuals selected from the population using the improbable random sampling method. "descriptive feature form," "obesity health belief model scale," "physical activity questionnaire" were used to collect data. in the analysis of data; percentile distribution, chi-square, fisher-freeman-halton exact test, t-test in independent groups, repeated measures anova test, friedman test, one way anova test, kruskall wallis test, and post hoc analyzes (bonferroni, games howell, dunn) were used.


Eligibility criteria:
inclusion criteria: * having a body mass index of 30 and above, * being able to use a computer * having a desk job (group from civil servant to manager) * not have a physical disability that would prevent physical activity, * for women, not being pregnant, * willingness to participate in the research. * having internet access exclusion criteria: * using weight-loss drugs * going to a dietitian * being on a diet * exercising

Keywords: face-to-face training health belief model obesity office workers physical activity web-based training
focal pain outcomes using configurations applied for lateral stimulation

Conditions: Chronic Pain

Summary: to evaluate programming modalities at various targets for focal foot, knee pain, and groin pain relief.


Eligibility criteria:
key inclusion criteria: * average unilateral foot, or knee or groin pain intensity of 6 or greater on a 0-10 numerical rating scale at baseline visit based on 7-day average nrs score * subject signed a valid, ec-approved informed consent form (icf) * willing and able to comply with all protocol-required procedures and assessments/evaluations * 18 years of age or older when written informed consent is obtained key exclusion criteria: * significant cognitive impairment at screening that, in the opinion of the investigator, would reasonably be expected to impair the study candidates to participate in the study * participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study

Keywords: spinal cord stimulation chronic pain
edaravone and argatroban stroke therapy study for acute ischemic stroke

Conditions: Stroke

Summary: edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. both the drugs were approved by the japanese government, and have frequently been used for the treatment of acute brain infarction in japan. the effect of combination therapy of these drugs, however, has not yet been elucidated. this study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke \< 24 hours of onset * measurable neurological deficits caused by the present attack, ranging from 1 to 22 of nihss score on admission exclusion criteria: * definite or possible cardiogenic brain infarction * definite lacunar infarction * prior ischemic stroke within 6 months * evidence of hemorrhagic brain infarction, epidural hematoma, intracerebral hematoma, or intraventricular hemorrhage * severe consciousness disturbances (semicoma to deep coma) * neurological signs clearing spontaneously * disability of 2 or more on mrs score before the index stroke aptt being out of the normal range or 1.5 times longer than the pretreatment value * if taking an oral anticoagulant, inr being 1.6 or more, or no inr data * treatment with urokinase, t-pa, heparin, ozagrel sodium, warfarin, or antiplatelet except for aspirin before enrollment * intravascular surgery, surgical operation, hyperbaric oxygen therapy, or hypothermia therapy before enrollment * serum creatinine \>1.5 mg/dl * severe hepatic or cardiac disorders, infectious disorders, dehydration, etc. * neoplasm * pregnancy * hypersensitivity to test drugs

Keywords: free radical scavenger selective thrombin inhibitor acute ischemic stroke (nonlacunar and noncardioembolic)
evaluation of different imaging modalities in regional lymph nodes staging in patients with breast cancer

Conditions: Breast Carcinoma Metastatic in Lymph Node

Summary: the regional lymph node status is considered to be an important prognostic factor regarding the long-term survival of breast cancer (bc) patients (cetin ia, et al . 2020). the knowledge of whether lymph nodes are tumor-infiltrated or not is essential since nodal involvement has decisive therapeutic consequences such as axillary lymph node dissection (alnd), axillary radiotherapy, and neoadjuvant or adjuvant systemic chemotherapy (diessner j et al . 2023). to provide individualized therapeutic options and optimized therapy.

the following data will be collected from electronic or paper medical data records as: 1) age 2 )sex 3)family history of breast cancer 4)menopausal status 5 )body mass index (bmi) 6) histological type of bc as reported in pathology 7) the results of the lymph node status. 8)registered data will be collected from the hospital databases and clinical sheers. 3 9) the gold standard reference in the evaluation of suspicious lymph nodes by nodal biopsy and postoperative pathology. imaging technique and interpretation the imaging diagnostic for bc (mri, ct, mammography, and ultrasound) patients are carried out by the department of diagnostic and interventional radiology of the hospitals in the research and interpreted by radiologists at the time of bc diagnosis. the radiological reports for each patient and each imaging technique will be analyzed about the lymph node status. the nodal status will be reported as benign, indeterminate, and infiltrated as stated by the acr lexicon. mammography and us for mammography, we will use full-field digital mammography systems with the option of additional tomosynthesis for further characterization of the primary tumor at nci with the commercially available the bc patients routinely receive an ultrasound exam including the evaluation of the breast and the axilla with the lymphatic drainage pathways as a part of the follow-up process active lymph nodes. p values lower than 0.05 will be considered significant.

Eligibility criteria:
inclusion criteria: 1. patient consenting to participate in the study. 2. patients who can tolerate the imaging modalities and have proven to tolerate the contrast agents . 3) breast cancer patients coming for an initial assessment with or without clinical regional lymph nodes positive status. 4) breast cancer patients planned to have(breast-conserving surgery or mastectomy)as well as lymph node surgeries(sentinel lymph node v biopsy and/or axillary lymph node dissection. exclusion criteria: 1)patients denying consent to participate in the study 2) patients who are not fit for further imaging evaluation (patients who exceed the weight limit, patients who are sensitive to contrast material, etc). 3) patients with bilateral mrm and ac -
an epidemiology study to determine the prevalence of egfr (epidermal growth factor receptor) mutations in russian patients with advanced nsclc (non-small cell lung cancer).

Conditions: Non-Small Cell Lung Cancer

Summary: this is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of egfr mutations in treatment-naive russian patients with cytologically verified advanced nsclc in russia.

this is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of egfr mutations in treatment-naive russian patients with cytologically verified advanced nsclc in russia. no additional procedures besides those already used in the routine clinical practice will be applied to the patients. treatment assignment will be done according to the current practice. it is planned to enrol approximately 300 subjects in russian federation. approximately 60 egfr m+ (mutation-positive) patients will be followed for 1.5 years. egfr mutations rate before treatment in cytology and plasma samples in treatment-naive patients with advanced nsclc in russia is considered as the primary outcome variable in this study.

Eligibility criteria:
inclusion criteria: * cytologically verified advanced (stages iiib - iv) nonsquamous (adenocarcinoma, large cell carcinoma) and mixed subtypes of nsclc and nsclc-nos), diagnosed before enrolment into the study * quality and quantity of the cytological sample material meeting the requirements of the molecular-genetic testing * no previous/ ongoing treatment for nsclc at the moment of recruitment exclusion criteria: * squamous nsclc cytologically confirmed subtype of cancer * any medical condition which on the opinion of the investigator may interfere the patient's participation in the study * quality and quantity of the cytological sample material insufficient for the molecular-genetic testing

Keywords: non-small cell lung cancer, nsclc, epidermal growth factor receptor, egfr
ct scores predict mortality in 2019-ncov pneumonia

Conditions: CT Scores Predict Mortality in 2019-nCoV Pneumonia

Summary: while 2019-ncov nucleic acid swab tests has high false positives rate, how to diagnose 2019-ncov pneumonia and predict prognosis by ct is very important.in this retrospective single-center study, we consecutively included suspected 2019-ncov pneumonia critical cases in the intensive care unit of wuhan third hospital from january 31, 2020 to february 16, 2020. the cases were confirmed by real-time rt-pcr, and all patients were evaluated with ct, cutoff values were obtained according to the yoden index, and were divided into high ct score group and low ct score group. epidemiological, demographic, clinical, and laboratory data were collected.


Eligibility criteria:
inclusion criteria: * all patients suspected of 2019 novel coronavirus infection. exclusion criteria: * patients' data are not available.
prevalence of seroconversion of hepatitis c virus among children with ckd on regular hemodialysis

Conditions: Hepatitis C Virus

Summary: observational cross sectional study for children with chronic kidney disease who on regular hemodialysis in assiut univeristy children hospital at dialysis unit, observe prevalence of serological seroconversion of hepatitis c virus and associated risk factors

hepatitis c virus (hcv) is a blood-borne pathogen that appears to be endemic in many parts of the world,the highest prevalence of hcv has been found in egypt (17-26%) the prevalence of hcv infection is higher in most subgroups of chronic kidney disease (ckd) patients than in the general population. as there is very little known about hcv infection in infants and children with ckd and this very limited information implies that the current guidelines do not apply directly and completely to this specific population, and as the kidney disease improving global outcomes (kdigo) has recommended that pediatric nephrologists and other physicians - in charge of caring for children with ckd - should carefully evaluate the extent to which the current guidelines may be extrapolated to children. hepatitis c virus (hcv) infection is a significant cause of morbidity and mortality in hemodialysis patients and observed as a major public health problem infecting 170 million people globally and hepatitis c virus (hcv) infection is one of the most common blood-borne infections in egypt, a large number of egyptians are exposed to infection due to low hygiene and sterilization measures in our community the patients who undergo maintenance hemodialysis (hd) treatment are at increased hazard of getting these infections and have a greater prevalence of hcv than the general population due to underlying impaired cellular immunity which increases their susceptibility to hcv infection the hemodialysis patients are exposed to prolonged vascular access and exposure to contaminated equipment and handling by medical staff, in addition the ckd patients require frequent blood transfusion to recover the anemia related with chronic kidney disease and this blood transfusion make a source for hcv infection the inadequate sterilization of medical equipments, invasive dialysis procedures, mode of dialysis, contaminated blood and blood products, duration of end stage kidney disease, sharing of dialysis equipment, insertion of an intravascular catheter and contact with contaminated hd equipments and supplies during hemodialysis, all these risk factors help in hcv infection in hemodialysis patients. in this study, the prevalence of seroconversion of hepatitis c virus among children with ckd on regular hemodialysis is to be assessed and its possible risk factors related to it

Eligibility criteria:
inclusion criteria: 1. age: from 1 year to 18 years 2. ckd children on regular hemodialysis for more than one month duration exclusion criteria: * 1-age: less than 1 year and more than 18 years 2- ckd children who are not on regular hemodialysis and for less than one month duration